Australian (ASX) Stock Market Forum

OPT - Opthea Limited

Jump to new
Was expecting a large push after they announced last dosing for the first of the trials taking place. In reading that announcement, I was made aware of the follow up’s continue for sometime yet. Primary report due this quarter. Let’s see how this goes (pun intended)
 
Well, in a trading halt with the first of the phase 3 trial results top line data to be released in the coming days. Much earlier than I expected. Fingers crossed it’s all positive. If so I can see a rerate occurring, a sudden fall in the price and another huge raise coming 🥴
 
Als2own said:
Well, in a trading halt with the first of the phase 3 trial results top line data to be released in the coming days. Much earlier than I expected. Fingers crossed it’s all positive. If so I can see a rerate occurring, a sudden fall in the price and another huge raise coming 🥴
Click to expand...
opt out

Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52

Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern
 
A reminder why I never invest in Bio-techs (anymore, took me a couple of times to learn the lesson.) Asymmetric risk is all wrong, high probability of a donut and low probability of a massive return. Its like buying lottery tickets.
 
galumay said:
A reminder why I never invest in Bio-techs (anymore, took me a couple of times to learn the lesson.) Asymmetric risk is all wrong, high probability of a donut and low probability of a massive return. Its like buying lottery tickets.
Click to expand...
But like any lottery, you have to be in it to win it. I noticed RPL down 15% on the news
 
galumay said:
Thats why I dont gamble!

This chart should be enough to convince anyone not to 'invest' in bio techs, but it wont, because gambling is an addiction!





View attachment 196042
Click to expand...
Thanks for sharing. Luckily not much cash in it to lose. Had some good advice from my eye doctor who just happens to be on the board of drug approval in WA and he told me that 90% of all tested eye drugs fail testing. As always if you have no background or idea of any field you invest (punt) on, seek advice or keep your cash in your pocket
 
diligence due? too late
.

The clinical trial result from hell has biotech investors on edge

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea. Now they risk being wiped out.
www.afr.com

This week, [CEO Megan] Baldwin was not answering questions. “I cannot add any more information that what is in our announcement,” she told AFR Weekend.

That has left investors in the dark about what happens next.

The prognosis is grim. Analysts called the trial results “catastrophic”, and Opthea must face up to an aggressive funding agreement with The Caryle Group to develop the treatment. Because of the high-risk nature of Baldwin’s vision, Opthea agreed to repay Carlyle four times the $US170 million it provided if things went wrong. This means Opthea owes Carlyle more than $US600 million ($955 million). The company only has $US114 million in cash.

Seasoned biotech investors says that type of funding deal is unusual but not unheard of. However, questions are being asked about why Baldwin and the board bet everything on a single drug without sharing the financial risk with a partner. In November, Baldwin told Forbes she had rejected offers from bigger pharmaceutical companies who were interested in a deal.

“They went and did this huge bet. You have to ask the board, why did they do this? They threw everything into it and bet the company on it. That comes down to board processes and what is really appropriate,” says Alison Cootes, a biotech investor and a former director at broking firm EG Capital.

“I always wondered why they didn’t partner, which would have mitigated the risk. It was a massive amount of money. Maybe they couldn’t get a partner. I don’t know if it will survive, I suspect not".
 
***** MONTHLY UPDATE FOR FULL CALENDAR YEAR 2025 STOCK TIPPING COMPETITION - @mullokintyre *****

March 2025 - Following on from last month's update for Opthea Limited (OPT), the clinical trial data release has been devastating for shareholders at the last moment and trading is currently suspended. The crucial moment for the stock appears to have been at the end of last month, as noted in last month's comment regarding the support level at $0.935, which didn't hold - see reference to this above with the comment made on 5th March. Hopefully numerous shareholders were able to see the signs before it was too late...

1743311418598.png
 
Your friendly reminder to NEVER, EVER take any notice of what brokers, analysts of advisors say. So here is Bell Potter, AFTER the company goes into probable permanent suspension and likely becomes a zero, putting a Sell on at $0.05 - down from their previous Buy at $1.30.

Just mind boggling.
IMG_8906.jpg
 
galumay said:
Your friendly reminder to NEVER, EVER take any notice of what brokers, analysts of advisors say. So here is Bell Potter, AFTER the company goes into probable permanent suspension and likely becomes a zero, putting a Sell on at $0.05 - down from their previous Buy at $1.30.

Just mind boggling.
View attachment 196749
Click to expand...
Always need to take care swimming with the sharks. Often not much left but the carcass 🥴
 
galumay said:
Your friendly reminder to NEVER, EVER take any notice of what brokers, analysts of advisors say. So here is Bell Potter, AFTER the company goes into probable permanent suspension and likely becomes a zero, putting a Sell on at $0.05 - down from their previous Buy at $1.30.

Just mind boggling.
View attachment 196749
Click to expand...
Such true words @galumay - stopped listening to brokers and analysts years ago...
 


Write your reply...
Top